BOZEMAN, Mont., July 19, 2018 /PRNewswire/ -- SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, announced today that the Company will present new preclinical data from its program developing novel selective small molecule Nav1.7 Inhibitors at the 17th World Congress on Pain®, scheduled to take place in Boston, Massachusetts, September 12-16, 2018. The poster will feature data supporting advancement of SiteOne's lead candidate for which the Company expects to file an IND submission by year end 2018.
"We are pleased that our preclinical results will be featured in an international scientific meeting this year," stated John Mulcahy, PhD, Co-inventor and Vice President of Research at SiteOne. "Since the inception of SiteOne Therapeutics, our team has prepared hundreds of new molecular entities targeting a unique binding site on Nav1.7. Optimization of potency and selectivity has yielded compounds exhibiting nanomolar potency and >1000 fold selectivity over other isoforms."
About Nav1.7
Nav1.7 is a voltage-gated sodium channel that plays a critical role in the generation and conduction of action potentials in sensory neurons and is required for the initiation of pain signals. Humans who are born with loss-of-function mutations in the gene encoding Nav1.7 cannot experience most types of pain, and conversely, those with a gain-of-function mutation of the Nav1.7 gene experience increased pain states. There has been immense interest in Nav1.7 channel blockers that have the potential to produce strong analgesia in acute and chronic pain while reducing the side effects associated with local anesthetics, opioids, or NSAIDs.
About SiteOne Therapeutics, Inc.
SiteOne Therapeutics is headquartered in Bozeman, Montana with a research laboratory in South San Francisco, California. SiteOne is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing pain therapies, such as NSAIDs or opioids. The company's therapeutic candidates are highly selective sodium ion channel 1.7 (Nav1.7) inhibitors based on naturally occurring small molecules. Given the critical role Nav1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products to serve patients that suffer from moderate to severe pain. For more information, visit SiteOne's Web site at www.siteonetherapeutics.com.
SOURCE SiteOne Therapeutics